Embecta (NASDAQ:EMBC) Shares Break Above 200-Day Moving Average – What’s Next?

Embecta Corp. (NASDAQ:EMBC)’s stock price passed above its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $6.37 and traded as high as $6.79. Embecta shares last traded at $6.52, with a volume of 1,153,748 shares traded.

Analyst Ratings Changes

Several brokerages have recently issued reports on EMBC. Zacks Research raised shares of Embecta from a “strong sell” rating to a “hold” rating in a research note on Friday, July 17th. Weiss Ratings raised shares of Embecta from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Embecta has a consensus rating of “Reduce” and a consensus price target of $11.00.

Embecta Trading Up 7.2%

The company has a 50-day moving average of $5.81 and a 200-day moving average of $6.37. The firm has a market capitalization of $369.42 million, a price-to-earnings ratio of 4.41 and a beta of 0.81.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Friday, August 7th. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.29. Embecta had a net margin of 8.59% and a negative return on equity of 19.25%. The firm had revenue of $271.70 million for the quarter, compared to the consensus estimate of $254.53 million. During the same period last year, the firm posted $1.12 EPS. Embecta’s quarterly revenue was down 8.1% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, research analysts forecast that Embecta Corp. will post 1.84 earnings per share for the current year.

Insider Activity at Embecta

In related news, CFO Jacob Elguicze acquired 20,000 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was acquired at an average cost of $4.67 per share, for a total transaction of $93,400.00. Following the completion of the acquisition, the chief financial officer directly owned 309,139 shares of the company’s stock, valued at approximately $1,443,679.13. The trade was a 6.92% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Jeffrey Mann bought 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were purchased at an average cost of $4.99 per share, for a total transaction of $99,800.00. Following the acquisition, the insider owned 262,915 shares of the company’s stock, valued at $1,311,945.85. This represents a 8.23% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have bought 70,000 shares of company stock worth $334,200. 1.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Embecta

Several large investors have recently added to or reduced their stakes in EMBC. Krensavage Asset Management LLC boosted its stake in shares of Embecta by 54.4% during the 2nd quarter. Krensavage Asset Management LLC now owns 1,135,340 shares of the company’s stock valued at $3,701,000 after buying an additional 400,000 shares during the period. Dimensional Fund Advisors LP boosted its position in Embecta by 7.8% during the first quarter. Dimensional Fund Advisors LP now owns 934,210 shares of the company’s stock worth $8,258,000 after purchasing an additional 67,374 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Embecta by 1.3% during the 1st quarter. Bank of New York Mellon Corp now owns 823,787 shares of the company’s stock worth $7,282,000 after buying an additional 10,468 shares during the period. Walleye Capital LLC bought a new stake in Embecta during the first quarter valued at about $7,013,000. Finally, CWA Asset Management Group LLC grew its holdings in Embecta by 43.4% in the 3rd quarter. CWA Asset Management Group LLC now owns 537,838 shares of the company’s stock valued at $3,044,000 after buying an additional 162,891 shares during the last quarter. 93.83% of the stock is owned by institutional investors and hedge funds.

Embecta Company Profile

Embecta Corp. (NASDAQ: EMBC) is a global diabetes-care company that develops, manufactures and sells products used to administer insulin and monitor blood glucose. Its portfolio includes pen needles, insulin syringes, safety needles and syringes, lancets, and other diabetes-management products designed for people with diabetes and the health care professionals who support them.

The company also offers digital and connected solutions intended to support diabetes management and improve the delivery of care.